新型抗结核药物
New Drugs for the Treatment of Tuberculosis.
机构信息
Department of Medicine, Johns Hopkins University School of Medicine, 1830 Building Room 450B, 1830 East Monument Street, Baltimore, MD 21287, USA.
Department of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Osler 527, Baltimore, MD, USA.
出版信息
Clin Chest Med. 2019 Dec;40(4):811-827. doi: 10.1016/j.ccm.2019.08.001.
Abstract
Tuberculosis (TB) has now surpassed HIV as the leading infectious cause of death, and treatment success rates are declining. Multidrug-resistant TB, extensively drug-resistant TB, and even totally drug-resistant TB threaten to further destabilize disease control efforts. The second wave in TB drug development, which includes the diarylquinoline, bedaquiline, and the nitroimidazoles delamanid and pretomanid, may offer options for simpler, shorter, and potentially all-oral regimens to treat drug-resistant TB. The "third wave" of TB drug development includes numerous promising compounds, including less toxic versions of older drug classes and candidates with novel mechanisms of action.
摘要
结核病（TB）现已超过艾滋病毒，成为导致死亡的主要传染病，且治疗成功率正在下降。耐多药结核病、广泛耐药结核病，甚至完全耐药结核病有可能进一步破坏疾病控制工作。TB 药物研发的第二波浪潮包括二芳基喹啉、贝达喹啉以及硝基咪唑类药物德拉马尼和普雷托马尼，它们可能为治疗耐药性结核病提供更简单、更短、且可能全口服的方案选择。TB 药物研发的“第三波浪潮”包括许多有前途的化合物，包括毒性较小的旧药类别和具有新型作用机制的候选药物。
相似文献
1
New Drugs for the Treatment of Tuberculosis.新型抗结核药物
Clin Chest Med. 2019 Dec;40(4):811-827. doi: 10.1016/j.ccm.2019.08.001.
2
Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB.耐药结核病治疗中的治疗失败和获得性贝达喹啉和德拉马尼耐药性。
Emerg Infect Dis. 2023 May;29(5):1081-1084. doi: 10.3201/eid2905.221716.
3
Bedaquiline and delamanid in tuberculosis.贝达喹啉与地拉米啶在结核病治疗中的应用
Expert Opin Pharmacother. 2015;16(15):2319-30. doi: 10.1517/14656566.2015.1080240. Epub 2015 Aug 19.
4
Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.贝达喹啉：一种用于耐多药结核病的新型二芳基喹啉。
Ann Pharmacother. 2014 Jan;48(1):107-15. doi: 10.1177/1060028013504087. Epub 2013 Nov 1.
5
Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.德拉马尼与贝达喹啉联合用于治疗耐多药和广泛耐药结核病：一项系统评价
Int J Mol Sci. 2017 Feb 7;18(2):341. doi: 10.3390/ijms18020341.
6
Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.贝达喹啉和/或德拉马尼治疗患者的文化转变。一项前瞻性多国研究。
Am J Respir Crit Care Med. 2021 Jan 1;203(1):111-119. doi: 10.1164/rccm.202001-0135OC.
7
Delamanid or pretomanid? A Solomonic judgement!德拉马尼还是普雷马尼？这真是一个棘手的问题！
J Antimicrob Chemother. 2022 Mar 31;77(4):880-902. doi: 10.1093/jac/dkab505.
8
TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis.TB-PRACTECAL：一项评估贝达喹啉和普托马尼德方案治疗成人耐多药肺结核的安全性和有效性的随机、对照、开放标签、Ⅱ-Ⅲ 期临床试验研究方案。
Trials. 2022 Jun 13;23(1):484. doi: 10.1186/s13063-022-06331-8.
9
Bedaquiline: a new hope to treat multi-drug resistant tuberculosis.贝达喹啉：治疗耐多药结核病的新希望。
Curr Top Med Chem. 2014;14(16):1866-74. doi: 10.2174/1568026614666140929114822.
10
The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.《endTB 观察性研究方案：贝达喹啉或含德拉马尼方案治疗耐多药结核病》。
BMC Infect Dis. 2019 Aug 20;19(1):733. doi: 10.1186/s12879-019-4378-4.
引用本文的文献
1
ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis.ACTG A5409（放射治疗肺结核）：一项2期随机、适应性、剂量范围、开放标签试验的研究方案，该试验旨在研究治疗肺结核的新型方案。
Trials. 2025 Aug 15;26(1):291. doi: 10.1186/s13063-025-08973-w.
2
ACTG A5409 (RAD-TB): Study Protocol for a Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis.ACTG A5409（RAD-TB）：一项针对治疗肺结核的新型方案的2期随机、适应性、剂量范围、开放标签试验的研究方案。
Res Sq. 2025 Mar 26:rs.3.rs-5931694. doi: 10.21203/rs.3.rs-5931694/v1.
3
Recent advancements in tuberculosis (TB) treatment regimens.结核病（TB）治疗方案的最新进展。
J Family Med Prim Care. 2025 Feb;14(2):521-525. doi: 10.4103/jfmpc.jfmpc_1237_24. Epub 2025 Feb 21.
4
Identification of Mycobacterium tuberculosis transcriptional repressor EthR inhibitors: Shape-based search and machine learning studies.结核分枝杆菌转录阻遏物EthR抑制剂的鉴定：基于形状的搜索和机器学习研究。
Heliyon. 2024 Feb 22;10(5):e26802. doi: 10.1016/j.heliyon.2024.e26802. eCollection 2024 Mar 15.
5
Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease.结核病和非结核分枝杆菌肺部疾病的治疗进展。
Nat Rev Drug Discov. 2024 May;23(5):381-403. doi: 10.1038/s41573-024-00897-5. Epub 2024 Feb 28.
6
Mapping Research Trends of Medications for Multidrug-Resistant Pulmonary Tuberculosis Based on the Co-Occurrence of Specific Semantic Types in the MeSH Tree: A Bibliometric and Visualization-Based Analysis of PubMed Literature (1966-2020).基于 MeSH 树中特定语义类型的共现对耐多药肺结核药物的研究趋势进行映射：对 PubMed 文献（1966-2020 年）进行的文献计量和可视化分析。
Drug Des Devel Ther. 2023 Jul 10;17:2035-2049. doi: 10.2147/DDDT.S409604. eCollection 2023.
7
Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections.唑烷酮类药物的并排分析，以估计针对分枝杆菌感染的治疗窗。
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0165522. doi: 10.1128/aac.01655-22. Epub 2023 Mar 15.
8
Challenges & Solutions for Recent Advancements in Multi-Drugs Resistance Tuberculosis: A Review.耐多药结核病近期进展的挑战与解决方案：综述
Microbiol Insights. 2023 Jan 30;16:11786361231152438. doi: 10.1177/11786361231152438. eCollection 2023.
9
Safety, Tolerability, Pharmacokinetics, and Metabolism of Telacebec (Q203) for the Treatment of Tuberculosis: a Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 1B Trial.泰乐菌素（Q203）治疗结核病的安全性、耐受性、药代动力学和代谢：一项随机、安慰剂对照、多次递增剂量的 1B 期临床试验。
Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0112322. doi: 10.1128/aac.01123-22. Epub 2022 Dec 12.
10
Pretomanid for tuberculosis treatment: an update for clinical purposes.用于结核病治疗的普瑞玛尼：临床应用最新进展
Curr Res Pharmacol Drug Discov. 2022;3:100128. doi: 10.1016/j.crphar.2022.100128. Epub 2022 Sep 9.
本文引用的文献
1
Mutations in () as a Novel Determinant of Resistance to Pretomanid and Delamanid in Mycobacterium tuberculosis.() 突变是导致结核分枝杆菌对丙硫异烟胺和德拉马尼耐药的新决定因素。
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01948-20.
2
Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans.德拉马尼在兔和人类结核性脑膜炎中的中枢神经系统药代动力学研究。
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.00913-19. Print 2019 Oct.
3
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.德拉马尼联合优化背景治疗方案治疗耐多药结核病的疗效和安全性：一项多中心、随机、双盲、安慰剂对照、平行分组 3 期临床试验。
Lancet Respir Med. 2019 Mar;7(3):249-259. doi: 10.1016/S2213-2600(18)30426-0. Epub 2019 Jan 7.
4
A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.药物敏感性肺结核治疗缩短方案的患者水平汇总分析。
Nat Med. 2018 Nov;24(11):1708-1715. doi: 10.1038/s41591-018-0224-2. Epub 2018 Nov 5.
5
High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.含贝达喹啉治疗方案治疗耐多药和广泛耐药结核病的高治疗成功率。
Eur Respir J. 2018 Dec 20;52(6). doi: 10.1183/13993003.01528-2018. Print 2018 Dec.
6
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.肺耐多药结核病成功治疗结果的相关因素：一项个体患者数据荟萃分析。
Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1.
7
Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.贝达喹啉替代二线注射剂治疗耐多药结核病的疗效改善：一项回顾性队列研究。
Clin Infect Dis. 2019 Apr 24;68(9):1522-1529. doi: 10.1093/cid/ciy727.
8
Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169).优化背景治疗方案治疗活动期结核病与下一代苯并噻嗪酮 Macozinone (PBTZ169)。
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.00840-18. Print 2018 Nov.
9
Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study.贝达喹啉对南非耐多药结核病患者死亡率的影响：一项回顾性队列研究。
Lancet Respir Med. 2018 Sep;6(9):699-706. doi: 10.1016/S2213-2600(18)30235-2. Epub 2018 Jul 11.
10
Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children.悬浮于水中的贝达喹啉片的相对生物利用度：对儿童给药的意义。
Br J Clin Pharmacol. 2018 Jun 27;84(10):2384-92. doi: 10.1111/bcp.13696.
Zotero 插件